JanOne Announces Strategic Plan to Divest its Legacy Businesses
September 16, 2020
Update on plans for sale of recycling business. Divesting will allow for focus on core life science assets LAS VEGAS, NV, Sept. 16, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, provided an update today regarding its initiatives to... READ MORE
September 3, 2020
Bottling and labeling partner Eurofins CDMO (Alphora Research, Inc.) to ensure JanOne clinical research maintains compliance with GMP and FDA regulations LAS VEGAS, NV Sept. 3, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability of its... READ MORE
August 28, 2020
Partnership to ensure clinical compliance for active and placebo dosing for PAD phase 2b trials planned for early 2021 and potential trials for treating Covid-19 vascular complications LAS VEGAS, NV Aug. 28, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving... READ MORE
August 26, 2020
Engineering batch for JAN101 complete and expectations are for GMP batch production to begin within 30 days LAS VEGAS, NV Aug. 26, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has successfully completed its initial engineering batch of JAN101.... READ MORE
August 21, 2020
-Introduction to JanOne scientific team -Strategy for upcoming planned Phase 2b trial of JAN101 -Business development updates, including planned COVID-19 treatment study and focus on commercialization and production capabilities LAS VEGAS, Aug. 21, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive,... READ MORE
JanOne to Present at The LD 500 Virtual Conference
August 19, 2020
Presentation to include recent and upcoming developments and overview of drug candidate JAN101 for the potential treatment of peripheral artery disease (PAD) as well as potential applications for COVID-19 vascular complications and planned IND submission process with FDA. Las Vegas, Aug. 19, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments to... READ MORE
August 11, 2020
JAN101 formulation ready for Phase 2b peripheral artery disease trials and for potential treatment of COVID-19 vascular inflammation LAS VEGAS, Aug. 11, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, together with its manufacturing partner, has successfully... READ MORE
August 6, 2020
Study to Explore JAN101's Potential to Treat Ischemia¹ and Endothelial dysfunction² in COVID-19 patients. LAS VEGAS, Aug. 6, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a world-leading,... READ MORE
JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101
August 4, 2020
LAS VEGAS, Aug. 4, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential... READ MORE
Optimized by Seraphinite Accelerator